Abstract:Background: Recent studies have highlighted the importance of the cell-free DNA (cfDNA) methylation profile in detecting breast cancer (BC) and its different subtypes. We investigated whether plasma cfDNA methylation, using cell-free Methylated DNA Immunoprecipitation and High-Throughput Sequencing (cfMeDIP-seq), may be informative in characterizing breast cancer in patients with BRCA1/2 germline mutations for early cancer detection and response to therapy. Methods: We enrolled 23 BC patients with germline mutation of BRCA1 and BRCA2 genes, 19 healthy controls without BRCA1/2 mutation, and two healthy individuals who carried BRCA1/2 mutations. Blood samples were collected for all study subjects at the diagnosis, and plasma was isolated by centrifugation. Cell-free DNA was extracted from 1 mL of plasma, and cfMeDIP-seq was performed for each sample. Shallow whole genome sequencing was performed on the immuno-precipitated samples. Then, the differentially methylated 300-bp regions (DMRs) between 25 BRCA germline mutation carriers and 19 non-carriers were identified. DMRs were compared with tumor-specific regions from public datasets to perform an unbiased analysis. Finally, two statistical classifiers were trained based on the GLMnet and random forest model to evaluate if the identified DMRs could discriminate BRCA-positive from healthy samples. Results: We identified 7,095 hypermethylated and 212 hypomethylated regions in 25 BRCA germline mutation carriers compared to 19 controls. These regions discriminate tumors from healthy samples with high accuracy and sensitivity. We show that the circulating tumor DNA of BRCA1/2 mutant breast cancers is characterized by the hypomethylation of genes involved in DNA repair and cell cycle. We uncovered the TFs associated with these DRMs and identified that proteins of the Erythroblast Transformation Specific (ETS) family are particularly active in the hypermethylated regions. Finally, we assessed that these regions could discriminate between BRCA positives from healthy samples with an AUC of 0.95, a sensitivity of 88%, and a specificity of 94.74%. Conclusions: Our study emphasizes the importance of tumor cell-derived DNA methylation in BC, reporting a different methylation profile between patients carrying mutations in BRCA1, BRCA2, and wild-type controls. Our minimally invasive approach could allow early cancer diagnosis, assessment of minimal residual disease, and monitoring of response to therapy.

Quantitative Detection of Methylation of FHIT and BRCA1 Promoters in the Serum of Ductal Breast Cancer Patients

Regulation of Dna Methylation on the Expression of the Fhit Gene Contributes to Cervical Carcinoma Cell Tumorigenesis

Abstract P3-01-02: Quantitative Analysis and Diagnostic Significance of Methylated SLC19A3 DNA in the Plasma of Breast Cancer Patients

Quantitative Analysis and Diagnostic Significance of Methylated SLC19A3 DNA in the Plasma of Breast and Gastric Cancer Patients

Hypomethylation Status of Mir-657 Promoter Region As Biomarker for Diagnosis of Hepatocellular Carcinoma: a Retrospective Study

Detection of aberrant methylation of a six-gene panel in serum DNA for diagnosis of breast cancer

DNA Methylation as a Noninvasive Epigenetic Biomarker for the Detection of Cancer.

Prediction of blood-based biomarkers and subsequent design of bisulfite PCR-LDR-qPCR assay for breast cancer detection

DNA Methylation Profiles and Their Diagnostic Utility in BC

Quantitative Detection of Promoter Hypermethylation in Multiple Genes in the Serum of Patients with Colorectal Cancer

Quantitative Assessment Of The Diagnostic Role Of Fhit Promoter Methylation In Non-Small Cell Lung Cancer

Establishment of HRM Method for Quantitative Determination for Methylation Level of DLC-1 Promoter in Prostate Cancer and Its Clinical Significance

[Detection of Free Tumor-Related DNA in the Serum of Breast Cancer Patients].

Circulating cell-free DNA-based methylation patterns for breast cancer diagnosis

Assessment of DNA methylation status in early stages of breast cancer development

Integrative analysis of DNA methylation and gene expression profiles identified potential breast cancer-specific diagnostic markers

Detection of 14-3-3 sigma (σ) promoter methylation as a noninvasive biomarker using blood samples for breast cancer diagnosis

Methylation signatures as biomarkers for non-invasive early detection of breast cancer: A systematic review of the literature

Differential methylation of circulating free DNA assessed through cfMeDiP as a new tool for breast cancer diagnosis and detection of BRCA1/2 mutation

DNA methylation signatures provide novel diagnostic biomarkers and predict responses of immune therapy for breast cancer

Pyrosequencing quantified methylation level of BRCA1 promoter as prognostic factor for survival in breast cancer patient